Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Ophthalmology

Managing the Risks: Complications and Side Effects

At a Glance

Idiopathic posterior uveitis can permanently threaten vision through macular edema, abnormal retinal blood vessels, or optic nerve damage. Steroids and immune-targeting medicines can also cause cataracts, high eye pressure, infections, or rare neurologic problems, so regular monitoring is essential.

Living with idiopathic posterior uveitis means managing a delicate balance. You must treat the inflammation aggressively enough to save your sight, while simultaneously monitoring for complications caused by both the disease and the medications used to treat it [1][2].

Understanding these risks allows you to become an active partner in your care, helping your doctor spot potential issues before they become permanent [3].

Complications from the Disease

If left untreated or undertreated, chronic inflammation can lead to structural changes in the eye that may cause permanent vision loss.

  • Macular Edema: This is the most common cause of vision loss in posterior uveitis, occurring in over 30% of active cases [4][5]. It involves swelling and fluid buildup in the macula (the center of the retina), which is responsible for your sharpest vision [6].
  • Retinal Neovascularization: Sometimes, inflammation starves the retina of oxygen, causing the eye to grow “leaky” new blood vessels [5]. These fragile vessels can bleed into the eye or lead to a retinal detachment [7][8].
  • Optic Nerve Damage: Inflammation can cause the optic nerve to swell (papillitis) or eventually wither (optic atrophy), which can permanently cut off the signal from your eye to your brain [9][1].

Complications from Local Treatment (Steroids)

As discussed in the treatment chapter, steroid implants (like Ozurdex or Yutiq) are powerful tools, but they “pay a tax” in the form of two very common side effects [2].

  • Cataracts: A cataract is a clouding of the eye’s natural lens. In long-term studies of the long-acting fluocinolone implant, roughly 70% to 74% of patients eventually required cataract surgery [2][10]. These rates vary widely depending on the device, dose, and time. The good news is that cataract surgery is a standard, highly successful procedure that can often restore the vision lost to the clouding [11].
  • Glaucoma and High Pressure: Steroids can interfere with the eye’s natural drainage system, leading to increased Intraocular Pressure (IOP) [12].
    • About 16% to 24% of patients with the fluocinolone implant may see their pressure rise significantly [10].
    • While most cases are managed with daily pressure-lowering drops, a small percentage (roughly 5% to 11%) may eventually need a specialized glaucoma surgery to protect the optic nerve [2][13].

Complications from Systemic Treatment

When you move to “steroid-sparing” medications or biologics, the risks shift from the eye to the rest of the body. For oral corticosteroids, do not stop abruptly, as this can cause adrenal suppression, blood pressure swings, and rebound inflammation.

Immunosuppressants (Methotrexate/Mycophenolate)

These drugs require regular blood monitoring (often more frequent when starting or changing doses, including CBC, liver tests, and renal function) to ensure your body is tolerating them well [14]. Both medications carry major reproductive risks, making strict pregnancy planning and contraception essential.

  • Liver Function: Both drugs can cause elevated liver enzymes, which usually resolves if the dose is adjusted [15][16].
  • Infection Risk: Because these drugs quiet the immune system, you may be more susceptible to infections. Mycophenolate, in particular, has been associated with a slightly higher risk of infections than methotrexate in some studies [17][18]. Call your doctor for unusual bruising, jaundice, or fever.

Biologics (Adalimumab/Humira)

Biologics are highly targeted, but they carry specific, rare risks that require careful screening.

  • Demyelinating Disease: In very rare cases, “anti-TNF” drugs like adalimumab have been linked to conditions that affect the protective coating of nerves (similar to Multiple Sclerosis) [19]. New neurologic symptoms have several possible causes and require clinician assessment, as they could represent a rare demyelinating adverse effect [20].
  • Tuberculosis (TB) Reactivation: If you have ever been exposed to TB, these drugs can “wake up” the infection. A TB screening strategy (which may include skin/blood tests and chest imaging) is required [21][22].

Monitoring for these side effects is a routine part of uveitis care. By catching these issues early—through eye pressure checks, blood tests, and imaging—your care team can keep your treatment safe while protecting your sight [3][14].

Common questions in this guide

What complications can idiopathic posterior uveitis cause?
Ongoing or undertreated inflammation can cause macular edema, which is swelling in the center of the retina, and can lead to permanent vision loss. It may also cause abnormal retinal blood vessels, retinal detachment, or damage to the optic nerve.
What are the most common side effects of steroid implants for posterior uveitis?
Steroid implants can increase the risk of cataracts and high pressure inside the eye, which can damage the optic nerve if not controlled. Cataracts may be treated with surgery, while high pressure is often managed with eye drops and sometimes glaucoma surgery.
How often will I need tests while taking methotrexate or mycophenolate for uveitis?
Your clinician will usually check blood counts, liver tests, and kidney function regularly, with more frequent testing when the medicine is started or the dose changes. These tests help detect changes in blood counts, liver problems, or other signs that your body is not tolerating treatment.
What screening is needed before starting adalimumab for idiopathic posterior uveitis?
Adalimumab and similar anti-TNF medicines require screening for tuberculosis, which may involve a skin or blood test and chest imaging. Tell your clinician about prior TB exposure and report new neurologic symptoms such as numbness, tingling, or balance changes.
Can I stop oral corticosteroids suddenly?
No—do not stop them without medical guidance. Abrupt withdrawal can cause adrenal suppression, blood pressure changes, and rebound inflammation, so your prescribing clinician should guide any dose reduction.
How can I tell whether vision loss is from active inflammation or permanent damage?
Your ophthalmologist can use an eye examination and imaging to assess whether inflammation, macular edema, scarring, or other structural damage is contributing to vision loss. Ask how your current findings compare with earlier examinations and what changes would suggest that treatment is working.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How much of my current vision loss is due to active inflammation versus structural damage like scarring or macular edema?
  2. 2.What is my current eye pressure, and how does it compare to my baseline before I started steroid treatments?
  3. 3.If I receive a steroid implant, what is the 'Plan B' if my eye pressure becomes difficult to control with drops alone?
  4. 4.How often will we perform blood tests to check my liver function and blood counts while I am on [methotrexate/mycophenolate]?
  5. 5.Given the rare risk of demyelinating disease with biologics, what specific neurologic symptoms should I watch for?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    [Prognostic factors in uveitis].

    Albaroudi N, Tijani M, Boutimzine N, et al.

    Journal francais d'ophtalmologie 2017; (40(9)):751-757 doi:10.1016/j.jfo.2017.04.005.

    PMID: 28882393
  2. 2

    Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results.

    Jaffe GJ, Pavesio CE,

    Ophthalmology 2020; (127(10)):1395-1404 doi:10.1016/j.ophtha.2020.04.001.

    PMID: 32624244
  3. 3

    Automatic measurement of choroidal thickness with swept-source optical coherence tomography in chronic Vogt-Koyanagi-Harada disease: 3 years' follow-up.

    Yamamoto-Rodríguez L, Anduaga-Beramendi A, Mediavilla-Vallespín R, et al.

    Journal of ophthalmic inflammation and infection 2024; (14(1)):62 doi:10.1186/s12348-024-00445-7.

    PMID: 39621182
  4. 4

    Disease of the Year: Differential Diagnosis of Uveitic Macular Edema.

    Agarwal A, Pichi F, Invernizzi A, Gupta V

    Ocular immunology and inflammation 2019; (27(1)):72-88 doi:10.1080/09273948.2018.1523437.

    PMID: 30273513
  5. 5

    Microvascular changes in the recurrent cystoid macular edema secondary to posterior noninfectious uveitis on optical coherence tomography angiography.

    Albano V, Guerriero S, Furino C, et al.

    International ophthalmology 2022; (42(11)):3285-3293 doi:10.1007/s10792-022-02327-0.

    PMID: 35598227
  6. 6

    Causes of Visual Loss in Uveitis: A Retrospective Study at a Tertiary Referral Centre.

    Al-Roubaie M, Beare N

    Cureus 2026; (18(1)):e102183 doi:10.7759/cureus.102183.

    PMID: 41585622
  7. 7

    Prevalence and risk factors for complicated immuno-mediated uveitis: experience in a tertiary hospital.

    Luque-Linero P, Espejo-González A, Navarrete-Navarrete N

    Archivos de la Sociedad Espanola de Oftalmologia 2024; (99(12)):540-547 doi:10.1016/j.oftale.2024.06.013.

    PMID: 39349141
  8. 8

    Recent advances in the diagnosis and treatment of refractory ocular inflammatory diseases: focus on uveitic macular edema, acute retinal necrosis, and vitreoretinal lymphoma.

    Takeda A, Yawata N, Sonoda KH

    Japanese journal of ophthalmology 2026; (70(1)):18-40 doi:10.1007/s10384-025-01310-3.

    PMID: 41366138
  9. 9

    Clinical Features of Ocular Sarcoidosis in Patients with Biopsy-proven Pulmonary Sarcoidosis in Serbia.

    Radosavljević A, Jakšić V, Pezo L, et al.

    Ocular immunology and inflammation 2017; (25(6)):785-789 doi:10.3109/09273948.2016.1167224.

    PMID: 27191355
  10. 10

    The 0.2-μg/day Fluocinolone Acetonide Intravitreal Implant in Chronic Noninfectious Posterior Uveitis: A 3-year Randomized Trial in India.

    Biswas J, Tyagi M, Agarwal M,

    Ophthalmology science 2024; (4(1)):100403 doi:10.1016/j.xops.2023.100403.

    PMID: 38027419
  11. 11

    Intravitreal Dexamethasone Implant in the Treatment of Non-infectious Uveitis

    Hasanreisoğlu M, Özdemir HB, Özkan K, et al.

    Turkish journal of ophthalmology 2019; (49(5)):250-257 doi:10.4274/tjo.galenos.2019.81594.

    PMID: 31650791
  12. 12

    Treatment of Non-infectious Uveitic Macular Edema with the Intravitreal Dexamethasone Implant.

    Nobre-Cardoso J, Champion E, Darugar A, et al.

    Ocular immunology and inflammation 2017; (25(4)):447-454 doi:10.3109/09273948.2015.1132738.

    PMID: 27003221
  13. 13

    Single Institution Experience of Intravitreal 0.18-mg Fluocinolone Acetonide Implant for Noninfectious Uveitis.

    Reddy AK, Pecen PE, Patnaik JL, Palestine AG

    Ophthalmology. Retina 2023; (7(1)):67-71 doi:10.1016/j.oret.2022.07.002.

    PMID: 35820567
  14. 14

    Use of immunomodulatory treatment for non-infectious uveitis: an International Ocular Inflammation Society report of real-world practice.

    Branford JA, Bodaghi B, Ferreira LB, et al.

    The British journal of ophthalmology 2025; (109(4)):482-489 doi:10.1136/bjo-2024-326239.

    PMID: 39472042
  15. 15

    Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial.

    Rathinam SR, Gonzales JA, Thundikandy R, et al.

    JAMA 2019; (322(10)):936-945 doi:10.1001/jama.2019.12618.

    PMID: 31503307
  16. 16

    Methotrexate Effectively Controls Ocular Inflammation in Japanese Patients With Non-infectious Uveitis.

    Harada Y, Hiyama T, Kiuchi Y

    Frontiers in medicine 2021; (8()):732427 doi:10.3389/fmed.2021.732427.

    PMID: 34869426
  17. 17

    Comparative effectiveness of disease-modifying antirheumatic drugs for patients with cardiac sarcoidosis.

    Brooks L, Kivlin W, Mohananey D, et al.

    Rheumatology (Oxford, England) 2025; (64(6)):3303-3308 doi:10.1093/rheumatology/keae692.

    PMID: 39724230
  18. 18

    Comparative Outcomes and Side Effects of Immunosuppressants and Tumor Necrosis Factor Inhibitors in Sarcoidosis: A Real-World Data Analysis.

    Chao WC, Liao SY

    Chest 2026; (169(4)):1006-1017 doi:10.1016/j.chest.2025.09.130.

    PMID: 41077383
  19. 19

    CNS Demyelination with TNF-α Blockers.

    Kemanetzoglou E, Andreadou E

    Current neurology and neuroscience reports 2017; (17(4)):36 doi:10.1007/s11910-017-0742-1.

    PMID: 28337644
  20. 20

    DADS neuropathy associated with anti-TNF-α therapy.

    McGinty RN, McNamara B, Moore H

    BMJ case reports 2015; (2015()).

    PMID: 26607186
  21. 21

    Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment.

    Park DI, Hisamatsu T, Chen M, et al.

    Intestinal research 2018; (16(1)):4-16 doi:10.5217/ir.2018.16.1.4.

    PMID: 29422793
  22. 22

    Prevalence of Latent and Active Tuberculosis Infection in Inflammatory Bowel Disease Patients Who Received Biological Treatment.

    Dashdamirova S, Eskazan T, Erzin YZ, et al.

    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2026; (37(5)):564-572 doi:10.5152/tjg.2026.25072.

    PMID: 41846472

This page is for informational purposes only and does not constitute medical advice. An ophthalmologist or uveitis care team should interpret your eye findings, test results, symptoms, and medication risks.

Get notified when new evidence is published on Idiopathic posterior uveitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.